1
|
Fazzari M, Lunghi G, Di Biase E, Maggioni M, Carsana EV, Cioccarelli L, Vigani L, Loberto N, Aureli M, Mauri L, Ciampa MG, Valsecchi M, Takato K, Imamura A, Ishida H, Ben Mariem O, Saporiti S, Palazzolo L, Chiricozzi E, Eberini I, Sonnino S. GM1 structural requirements to mediate neuronal functions. Glycoconj J 2023; 40:655-668. [PMID: 38100017 DOI: 10.1007/s10719-023-10141-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 11/02/2023] [Accepted: 12/01/2023] [Indexed: 01/16/2024]
Abstract
Since the 1980s, it has been known that the administration of ganglioside GM1 to cultured cells induced or enhanced neuronal differentiation. GM1 mechanism of action relies on its direct interaction and subsequent activation of the membrane tyrosine kinase receptor, TrkA, which naturally serves as NGF receptor. This process is mediated by the sole oligosaccharide portion of GM1, the pentasaccharide β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-β-Gal-(1-4)-β-Glc. Here we detailed the minimum structural requirements of the oligosaccharide portion of GM1 for mediating the TrkA dependent neuritogenic processing. By in vitro and in silico biochemical approaches, we demonstrated that the minimal portion of GM1 required for the TrkA activation is the inner core of the ganglioside's oligosaccharide β-Gal-(1-3)-β-GalNAc-(1-4)-[α-Neu5Ac-(2-3)]-β-Gal. The addition of a sialic acid residue at position 3 of the outer galactose of the GM1 oligosaccharide, which forms the oligosaccharide of GD1a, prevented the interaction with TrkA and the resulting neuritogenesis. On the contrary, the addition of a fucose residue at position 2 of the outer galactose, forming the Fucosyl-GM1 oligosaccharide, did not prevent the TrkA-mediated neuritogenesis.
Collapse
Affiliation(s)
- Maria Fazzari
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Giulia Lunghi
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Erika Di Biase
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Margherita Maggioni
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Emma Veronica Carsana
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Laura Cioccarelli
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Laura Vigani
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Nicoletta Loberto
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Massimo Aureli
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Laura Mauri
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Maria Grazia Ciampa
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Manuela Valsecchi
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
| | - Koichi Takato
- Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
| | - Akihiro Imamura
- Department of Applied Bioorganic Chemistry, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
- Institute for Glyco-core Research (iGCORE), Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
| | - Hideharu Ishida
- Department of Applied Bioorganic Chemistry, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
- Institute for Glyco-core Research (iGCORE), Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
| | - Omar Ben Mariem
- Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Università degli Studi di Milano, Milano, Italy
| | - Simona Saporiti
- Analytical Excellence & Program Management, Merck Serono S.p.A, Rome, Italy
| | - Luca Palazzolo
- Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Università degli Studi di Milano, Milano, Italy
| | - Elena Chiricozzi
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy.
| | - Ivano Eberini
- Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Università degli Studi di Milano, Milano, Italy
- Data Science Research Center, Università degli Studi di Milano, Milano, Italy
| | - Sandro Sonnino
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy.
| |
Collapse
|
2
|
Lunghi G, Carsana EV, Loberto N, Cioccarelli L, Prioni S, Mauri L, Bassi R, Duga S, Straniero L, Asselta R, Soldà G, Di Fonzo A, Frattini E, Magni M, Liessi N, Armirotti A, Ferrari E, Samarani M, Aureli M. β-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration. Cells 2022; 11:cells11152343. [PMID: 35954187 PMCID: PMC9367513 DOI: 10.3390/cells11152343] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 07/25/2022] [Accepted: 07/27/2022] [Indexed: 02/06/2023] Open
Abstract
β-glucocerebrosidase is a lysosomal hydrolase involved in the catabolism of the sphingolipid glucosylceramide. Biallelic loss of function mutations in this enzyme are responsible for the onset of Gaucher disease, while monoallelic β-glucocerebrosidase mutations represent the first genetic risk factor for Parkinson’s disease. Despite this evidence, the molecular mechanism linking the impairment in β-glucocerebrosidase activity with the onset of neurodegeneration in still unknown. In this frame, we developed two in vitro neuronal models of β-glucocerebrosidase deficiency, represented by mouse cerebellar granule neurons and human-induced pluripotent stem cells-derived dopaminergic neurons treated with the specific β-glucocerebrosidase inhibitor conduritol B epoxide. Neurons deficient for β-glucocerebrosidase activity showed a lysosomal accumulation of glucosylceramide and the onset of neuronal damage. Moreover, we found that neurons react to the lysosomal impairment by the induction of their biogenesis and exocytosis. This latter event was responsible for glucosylceramide accumulation also at the plasma membrane level, with an alteration in lipid and protein composition of specific signaling microdomains. Collectively, our data suggest that β-glucocerebrosidase loss of function impairs the lysosomal compartment, establishing a lysosome–plasma membrane axis responsible for modifications in the plasma membrane architecture and possible alterations of intracellular signaling pathways, leading to neuronal damage.
Collapse
Affiliation(s)
- Giulia Lunghi
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20054 Milan, Italy; (G.L.); (E.V.C.); (N.L.); (L.C.); (S.P.); (L.M.); (R.B.)
| | - Emma Veronica Carsana
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20054 Milan, Italy; (G.L.); (E.V.C.); (N.L.); (L.C.); (S.P.); (L.M.); (R.B.)
| | - Nicoletta Loberto
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20054 Milan, Italy; (G.L.); (E.V.C.); (N.L.); (L.C.); (S.P.); (L.M.); (R.B.)
| | - Laura Cioccarelli
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20054 Milan, Italy; (G.L.); (E.V.C.); (N.L.); (L.C.); (S.P.); (L.M.); (R.B.)
| | - Simona Prioni
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20054 Milan, Italy; (G.L.); (E.V.C.); (N.L.); (L.C.); (S.P.); (L.M.); (R.B.)
| | - Laura Mauri
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20054 Milan, Italy; (G.L.); (E.V.C.); (N.L.); (L.C.); (S.P.); (L.M.); (R.B.)
| | - Rosaria Bassi
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20054 Milan, Italy; (G.L.); (E.V.C.); (N.L.); (L.C.); (S.P.); (L.M.); (R.B.)
| | - Stefano Duga
- Department of Biomedical Sciences, Humanitas University, 20090 Milan, Italy; (S.D.); (L.S.); (R.A.); (G.S.)
- Humanitas Clinical and Research Center—IRCCS, Via Manzoni 56, 20072 Milan, Italy
| | - Letizia Straniero
- Department of Biomedical Sciences, Humanitas University, 20090 Milan, Italy; (S.D.); (L.S.); (R.A.); (G.S.)
- Humanitas Clinical and Research Center—IRCCS, Via Manzoni 56, 20072 Milan, Italy
| | - Rosanna Asselta
- Department of Biomedical Sciences, Humanitas University, 20090 Milan, Italy; (S.D.); (L.S.); (R.A.); (G.S.)
- Humanitas Clinical and Research Center—IRCCS, Via Manzoni 56, 20072 Milan, Italy
| | - Giulia Soldà
- Department of Biomedical Sciences, Humanitas University, 20090 Milan, Italy; (S.D.); (L.S.); (R.A.); (G.S.)
- Humanitas Clinical and Research Center—IRCCS, Via Manzoni 56, 20072 Milan, Italy
| | - Alessio Di Fonzo
- IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy; (A.D.F.); (E.F.); (M.M.)
| | - Emanuele Frattini
- IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy; (A.D.F.); (E.F.); (M.M.)
| | - Manuela Magni
- IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy; (A.D.F.); (E.F.); (M.M.)
| | - Nara Liessi
- Analytical Chemistry Facility, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy; (N.L.); (A.A.)
| | - Andrea Armirotti
- Analytical Chemistry Facility, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy; (N.L.); (A.A.)
| | - Elena Ferrari
- Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy;
| | - Maura Samarani
- Department of Cell Biology and Infection, Institut Pasteur, 75015 Paris, France;
| | - Massimo Aureli
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20054 Milan, Italy; (G.L.); (E.V.C.); (N.L.); (L.C.); (S.P.); (L.M.); (R.B.)
- Correspondence: ; Tel.: +39-025-033-0364
| |
Collapse
|